Amazon launches cancer vaccine clinical trial in partnership with Fred Hutchinson

Amazon launches cancer vaccine clinical trial in partnership with Fred Hutchinson


Andy Jassy, chief executive officer of Amazon.Com Inc., during the GeekWire Summit in Seattle, Washington, U.S., on Tuesday, Oct. 5, 2021.

David Ryder | Bloomberg | Getty Images

Amazon is developing cancer vaccines in collaboration with the Fred Hutchinson Cancer Research Center, and it recently launched an FDA-approved clinical trial.

Amazon and Fred Hutchinson are looking to recruit 20 participants over the age of 18 for the early stage, or phase 1, trial, according to a filing on clinicaltrials.gov, a database of clinical trials run by the National Library of Medicine. The goal is to develop “personalized vaccines” that can treat breast cancer and melanoma, a form of skin cancer, the filing states.

Fred Hutchinson is listed as a sponsor of the study, while Amazon is listed as a collaborator, according to the filing. News of the partnership was first reported by Business Insider. The study was first posted last October, and it began June 9. It’s expected to be complete by Nov. 1 of 2023.

Fred Hutch and Amazon confirmed the partnership. An Amazon spokesperson said it’s being led by Fred Hutch.

“Amazon is contributing scientific and machine learning expertise to a partnership with Fred Hutch to explore the development of a personalized treatment for certain forms of cancer,” the spokesperson told CNBC in a statement. “It’s very early, but Fred Hutch recently received permission from the U.S. Food and Drug Administration to proceed with a Phase I clinical trial, and it’s unclear whether it will be successful. This will be a long, multi-year process — should it progress, we would be open to working with other organizations in health care and life sciences that might also be interested in similar efforts.”

Amazon has deepened its presence in the health-care industry in recent years. The company in 2020 launched an online pharmacy, it has ramped up its telehealth service, called Amazon Care, and it has sought to develop at-home medical diagnostics.

A secretive research and development group inside Amazon, known as Grand Challenge, initially oversaw the cancer vaccine effort, according to Business Insider, which cited people familiar with the matter. It’s now under the purview of a cancer research team reporting to Amazon’s vice president of devices, Robert Williams, Business Insider reported.

WATCH: Andy Jassy’s priority is to chart a next generation path for growth, says Madron’s McIlwain



Source

China Nvidia rival Cambricon adds to  billion rally with 4,000% revenue jump
Technology

China Nvidia rival Cambricon adds to $40 billion rally with 4,000% revenue jump

China is focusing on large language models in the artificial intelligence space. Blackdovfx | Istock | Getty Images Chinese semiconductor firm Cambricon posted record profit in the first half of the year underscoring how local challengers to Nvidia are gaining traction as Beijing looks to boost its domestic industry. Cambricon is among a plethora of […]

Read More
Microsoft had police remove protesters who stormed office over work with Israeli military
Technology

Microsoft had police remove protesters who stormed office over work with Israeli military

Brad Smith, president of Microsoft Corp., at the Web Summit conference in Vancouver, British Columbia, Canada, on Wednesday, May 28, 2025. The annual conference gathers key industry figures in technology. James MacDonald | Bloomberg | Getty Images Microsoft asked police to remove people who improperly entered a building at its headquarters in protest of the […]

Read More
Okta raises forecast as CEO says economic conditions were ‘better than we thought’
Technology

Okta raises forecast as CEO says economic conditions were ‘better than we thought’

Okta CEO Todd McKinnon appears on CNBC in September 2018. Anjali Sundaram | CNBC Okta shares rose 4% in extended trading on Tuesday after the identity software maker reported fiscal results that exceeded Wall Street projections. Here’s how the company did in comparison with LSEG consensus: Earnings per share: 91 cents adjusted vs. 84 cents […]

Read More